Eurofins Scientific has reached an agreement with Element Materials Technology to acquire its Life Sciences Testing Services business in North America. This acquisition reflects Eurofins’ continued commitment to investing in scientific excellence and capabilities to better serve clients across North America.
Element’s North America Life Sciences Testing Services business includes a network of 750 staff and 27 laboratories and facilities, providing biopharmaceutical product testing, environmental testing, and food testing services throughout the United States and Canada. Ten of these sites will join Eurofins BioPharma Product Testing and Medical Device Services, adding approximately 380 employees to our North American network. These 10 sites are located in Acton, MA; Ann Arbor, MI; Bend, OR; Concord, CA; Eagan, MN; Iowa City, IA; Midland, MI; Minnetonka, MN; Santa Fe Springs, CA; and Toronto, ON, CA.
What This Means for Clients
This acquisition expands the depth and reach of the Eurofins network of BioPharma Product Testing and Medical Device Services companies across North America, providing clients with:
- Greater regional access to environmental monitoring and facility validation services in the Northeast and Pacific Northwest, delivering critical support closer to business operations.
- Expanded raw materials testing capabilities, particularly in the West, to support greater flexibility and continuity for product development and quality programmes.
- Expanded medical device services expertise, including mechanical testing and specialised support for cardiovascular, neurovascular, and orthopaedic devices, with added regional presence in Minnesota.
- Access to Iowa City’s SENTRY Antimicrobial Surveillance Program, one of the world’s longest-running public health initiatives, supporting global pathogen and antimicrobial resistance surveillance through the characterisation of nearly one million bacterial and fungal isolates. Its capabilities also include bacteriophage characterisation and assays, clinical trial support, and next-generation sequencing.
- A broader small molecule testing footprint, offering more options to align testing support with project timelines, locations, and technical requirements.
Looking Ahead
This expanded network brings more than additional capacity; it strengthens access to specialised scientific expertise, broader testing capabilities, and regional laboratory support across North America. By integrating Element’s Life Sciences Testing Services business into the established Eurofins network, we are even better positioned to support clients’ evolving testing needs with reliable services, technical depth, and the quality standards expected from Eurofins companies.
For more information contact us at: BioPharmaProductTesting@BPT.EurofinsUS.com or visit: Eurofins BioPharma Product Testing.